TrialJAMA dermatology2020

Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.

Matthias Augustin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.